Family medicine clinicians titrating GLP-1 therapy must weigh total weight loss against body composition outcomes, as loss of lean mass carries independent clinical consequences including reduced functional capacity, impaired glucose metabolism, and increased fall risk, particularly in older patients. If tirzepatide produces greater lean mass loss despite superior overall weight reduction, this differential may inform agent selection in patients with pre-existing sarcopenia, frailty, or low skeletal muscle index at baseline. Monitoring body composition rather than weight alone becomes a more defensible clinical standard when the two leading agents appear to diverge on this outcome.
This observational study examined differences in body composition changes between patients treated with tirzepatide and those treated with semaglutide, with a specific focus on lean mass loss as a distinct outcome from total weight reduction. The central finding was that a greater proportion of patients on tirzepatide lost more than 5% of their lean mass compared to patients on semaglutide, suggesting a differential impact on skeletal muscle preservation between the two agents despite tirzepatide’s generally superior weight loss efficacy.
For prescribers managing patients with obesity or metabolic disease, these findings carry meaningful clinical implications, particularly for populations where preserving lean mass is a priority, including older adults, individuals with sarcopenic obesity, those with type 2 diabetes at risk for functional decline, and patients undergoing concurrent resistance training. While tirzepatide’s dual GIP and GLP-1 receptor agonism drives more robust reductions in total body weight and fat mass, the data suggest this may come with a greater absolute or proportional reduction in lean tissue. Clinicians should consider incorporating body composition monitoring, including DEXA or validated bioelectrical impedance assessments, into the management of patients on GLP-1 and dual incretin therapies, and may wish to emphasize resistance exercise and adequate protein intake as standard adjuncts to pharmacotherapy regardless of agent chosen.
Based on a preprint observational study, more patients taking tirzepatide (Eli Lilly) lost greater than 5% of their lean mass compared to patients taking semaglutide (Novo Nordisk), suggesting a potential difference in body composition outcomes between these two GLP-1 receptor agonist therapies. For GLP-1 prescribers, this finding raises clinically relevant questions about preserving skeletal muscle during weight loss treatment, particularly in older adults or patients at risk for sarcopenia, where lean mass loss carries meaningful functional consequences. A critical limitation is that this is a preprint observational study with no reported sample size, meaning the findings have not yet undergone peer review and confounding variables such as baseline diet, physical activity, and protein intake have likely not been fully controlled. Family medicine providers prescribing GLP-1 therapies should consider routinely incorporating resistance exercise counseling and adequate dietary protein guidance for all patients on these medications, regardless of which agent is prescribed, until higher-quality comparative data are available.
“The emerging signal around differential lean mass preservation between tirzepatide and semaglutide is clinically meaningful and deserves serious attention, even at the preprint stage. If this finding holds up under peer review, it has real implications for how we sequence and select these agents, particularly in older patients or those with sarcopenic obesity where preserving muscle is not just a cosmetic concern but a functional and longevity issue. In my practice, this reinforces why I am already having explicit conversations with patients about resistance training and protein intake as non-negotiable adjuncts to any GLP-1 or GIP-based therapy. The drug choice matters, but so does what we build around it.”
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What are tirzepatide and semaglutide?
Tirzepatide (sold as Mounjaro or Zepbound) is made by Eli Lilly, and semaglutide (sold as Ozempic or Wegovy) is made by Novo Nordisk. Both are GLP-1 receptor agonists used to treat obesity and related metabolic conditions. They work by regulating appetite and blood sugar to promote weight loss.
What does “lean mass” mean and why does it matter?
Lean mass refers to the weight of everything in your body except fat, including muscle, bone, and organs. Preserving lean mass during weight loss is important because muscle supports metabolism, physical strength, and long-term health outcomes. Losing too much lean mass can increase the risk of weakness, fatigue, and metabolic slowdown.
What did this study find about muscle loss between the two medications?
The preprint study found that more patients taking tirzepatide lost over 5% of their lean mass compared to patients taking semaglutide. This suggests semaglutide may have a relative advantage in preserving muscle tissue during weight loss. However, this is a preprint, meaning it has not yet completed formal peer review.
Should I be worried about losing muscle on GLP-1 therapy?
Some degree of lean mass loss is common with any significant weight loss, whether from medication, diet, or surgery. The goal is to minimize that loss while maximizing fat loss, which is why your doctor may recommend protein intake and resistance exercise alongside your medication. Talk with your physician about strategies tailored to your situation.
Does losing more weight automatically mean losing more muscle?
Not necessarily, but the two can be related if the weight loss happens too rapidly or without adequate protein and exercise support. The type of tissue lost depends on many factors including diet quality, physical activity, and the medication being used. Individualized lifestyle guidance is a critical part of any GLP-1 treatment plan.
What can I do to protect my muscle while on GLP-1 therapy?
Resistance training and adequate daily protein intake are the two most evidence-supported strategies for preserving lean mass during weight loss. Most guidelines recommend at least 1.2 to 1.6 grams of protein per kilogram of body weight per day for patients undergoing significant caloric restriction. Your care team can help you build a plan that fits your health status and goals.
Is one GLP-1 medication better than another for everyone?
No single medication is universally superior for every patient, because individual responses vary based on metabolic health, genetics, lifestyle, and treatment goals. Studies like this one provide population-level data that can inform clinical decisions, but your physician will consider your full picture. The best medication for you is one that achieves your goals with the most favorable side effect profile.
What is a preprint study and should I trust it?
A preprint is a research study that has been shared publicly before going through the peer review process, which is when other scientists formally evaluate the methodology and conclusions. Preprints can provide early signals about important findings, but they should be interpreted cautiously until peer review is complete. Your physician can help you understand what the evidence means for your care.
Will my doctor switch my medication based on studies like this one?
Your physician will consider emerging research alongside your personal response to therapy, your side effect profile, your insurance coverage, and your overall health goals before making any changes. A single preprint study is rarely enough on its own to justify switching medications. Ongoing monitoring and open communication with your care team are the best ways to ensure your treatment remains appropriate.
How will my doctor monitor my muscle mass during GLP-1 treatment?
Some clinicians use tools like DEXA scans, bioelectrical impedance analysis, or grip strength assessments to track body composition changes over time. Regular follow-up visits that include weight trends, functional assessments, and lab work are also part of responsible GLP-1 management. Ask your doctor what monitoring approach makes the most sense given your individual treatment plan.
